Haemonetics (HAE) Peer Comparison

$117.11

$-1.10 (-0.93%)

As on 21-Oct-2026 16:00EDT

Market cap

$5,518 Mln

Revenue (TTM)

$1,352 Mln

P/E Ratio

58.6

P/B Ratio

5.8

Div. Yield

0 %

Edit

	Haemonetics (HAE)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	10X Genomics Inc (TXG)
Market cap ($ Mln)	5,518	12,652	11,137	10,883	9,102
Revenue ($ Mln)	1,352	1,505	785	6,561	617
Net Profit ($ Mln)	96.29	160.59	41.54	-578.00	-75.13
Net Margin (%)	7.12	10.67	5.29	-8.81	-12.18
RoE (%)	11.01	10.86	1.97	-10.33	-9.26
Price to Earnings	58.59	78.92	240.30	--	--
Price-To-Book	5.81	8.22	4.93	1.77	11.93

Income Statement ($ Mln)

	Haemonetics (HAE)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	10X Genomics Inc (TXG)
Operating Revenue	1,334.03	1,403.67	738.26	6,552.20	642.82
Cost of Revenue	590.44	461.23	390.63	4,412.80	198.94
Gross Profit	743.59	942.44	347.62	2,139.40	443.88
Operating Expenses	502.19	753.19	288.05	2,385.60	554.77
Operating Profit (EBIT)	241.40	189.25	59.58	-246.20	-110.89
Other Income	--	--	--	--	--
Profit before Tax	128.03	205.13	62.38	-441.30	-39.91
Provision for Tax	30.72	27.44	13.49	88.90	3.64
Profit after Tax (Net Income)	97.31	177.69	48.89	-530.20	-43.54
Minority Interest	--	--	--	--	--
Consolidated Profit	167.68	177.69	--	--	--

	Haemonetics (HAE)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	10X Genomics Inc (TXG)
Shareholder's Funds	796.32	1,427.60	2,106.13	5,565.00	796.33
Minority Interest	--	--	--	--	--
Non-Current Liabilities	1,317.01	215.78	707.74	4,850.80	91.59
Current Liabilities	282.60	183.13	135.83	1,378.90	153.45
Total Liabilities	2,395.93	1,826.52	2,949.70	11,794.70	1,041.37

	Haemonetics (HAE)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	10X Genomics Inc (TXG)
Non-Current Assets	1,561.05	609.84	1,812.31	9,343.50	356.91
Current Assets	834.88	1,216.68	1,137.39	2,451.20	684.45
Total Assets	2,395.93	1,826.52	2,949.70	11,794.70	1,041.37
Total Debt*	1,224.58	219.70	689.95	3,946.30	157.74
Net Current Assets	552.28	1,033.55	1,001.56	1,072.30	531.00

	Haemonetics (HAE)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	10X Genomics Inc (TXG)
Cash From Operating Activities	293.22	238.66	117.42	623.80	136.05
Cash Flow from Investing Activities	-179.55	-404.59	-298.47	-130.50	-13.44
Cash from Financing Activities	-178.46	26.53	-15.21	-409.40	6.80
Net Cash Inflow / Outflow	--	--	--	--	--

	Haemonetics (HAE)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	10X Genomics Inc (TXG)
ROCE (%)	4.79	11.76	1.79	-5.43	-4.99
ROE (%)	12.03	13.78	2.40	-9.20	-5.78
ROA (%)	4.02	10.58	1.69	-4.44	-4.44
EBIT Margin (%)	--	--	--	--	--
Net Margin (%)	7.29	12.66	6.62	-8.09	-6.77
Cash Profit Margin (%)	--	--	--	--	--

	Haemonetics (HAE)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	10X Genomics Inc (TXG)
Revenue Growth (%)	-0.02	0.17	0.16	-0.03	0.05
EBIT Growth (%)	--	--	--	--	--
Net Profit Growth (%)	-41.97	1,168.11	291.64	-174.52	76.16
EPS Growth (%)	-0.38	11.64	2.90	-1.75	0.77
Book Value Growth (%)	--	--	--	--	--

	Haemonetics (HAE)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	10X Genomics Inc (TXG)
Price / Earnings	26.77	68.93	189.42	-14.68	-47.60
Price / Book Value	3.27	8.58	4.40	1.40	2.60
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	13.35	53.25	50.32	81.94	436.68
Market Cap ($ Cr)	--	--	--	--	--

	Haemonetics (HAE)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	10X Genomics Inc (TXG)
Debt to Equity	1.54	0.15	0.33	0.71	0.20
Short term debt to equity ratio	0.01	0.01	0.01	0.01	0.01
Current Ratio	2.95	6.64	8.37	1.78	4.46
Quick Ratio	1.87	4.29	7.12	1.18	4.09
Interest Coverage	5.46	157.46	3.69	-1.60	--

	Haemonetics (HAE)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)	10X Genomics Inc (TXG)
Debtors to sales (%)	16.26	13.54	21.48	16.40	12.83
Asset Turnover	0.55	0.84	0.26	0.55	0.66
Receivable days	57.43	46.54	72.41	58.79	48.40
Inventory Days	207.70	331.92	146.53	64.13	128.01
Payable days	36.51	26.16	29.05	58.13	23.54
Cash Conversion Cycle	228.62	352.30	189.88	64.79	152.87

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.